Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children

NCT02879747

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Short Stature
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
4-18 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Participated in the 'GH-dose catch-up study' 98- 0198-003.

- Midparental height reached (difference less than 0.6 SDS)

- Prepubertal at start of the study (girls =B 1, boys: testes :<; 3ml).

- Signed written informed consent from the patient's parents (and the child if old enough)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Disease affecting growth other than correctly treated hypothyroidism.


- Incapable of following the study protocol (i.e. bad compliance in the previous study).


- Puberty (> breast stage 2, or testes > 4ml).


- Poor compliance.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Advanced Information
Descriptive Information
Brief Title  ICMJE Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children
Official Title  ICMJE Individualizing the Dose of Growth Hormone (GH) to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children Within TR 98-0198-003
Brief Summary The objective was to study whether normal growth velocity can be maintained with adapted GH dosage in GH treated prepubertal children who have responded to GH treatment with fulfilled catch up growth (=difference to target height reached, less than - 0.6 SDS).
Detailed Description The aim of the trial is to study the effect of adapted GH treatment in order to find an individualized GH dose maintaining normal growth velocity close to target height SDS and normal metabolism after fulfilled catch up growth in prepubertal children treated with individual doses of GH within the trial 98-0198-003 (1). The overall aim is to find for the individual the lowest effective GH dose during maintenance period, maintaining normal growth velocity and metabolism, i.e. a satisfactory biological active dose.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Short Stature
Intervention  ICMJE Drug: Genotropin
Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
Study Arms  ICMJE
  • Active Comparator: Interventional
    Unchanged dose Genotropin
    Intervention: Drug: Genotropin
  • Active Comparator: Interventional 2
    reduced dose 50% Genotropin
    Intervention: Drug: Genotropin
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 22, 2016)
99
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 2017
Actual Primary Completion Date March 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participated in the 'GH-dose catch-up study' 98- 0198-003.
  • Midparental height reached (difference less than 0.6 SDS)
  • Prepubertal at start of the study (girls =B 1, boys: testes :<; 3ml).
  • Signed written informed consent from the patient's parents (and the child if old enough)

Exclusion Criteria:

  • Disease affecting growth other than correctly treated hypothyroidism.
  • Incapable of following the study protocol (i.e. bad compliance in the previous study).
  • Puberty (> breast stage 2, or testes > 4ml).
  • Poor compliance.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 4 Years to 18 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02879747
Other Study ID Numbers  ICMJE NRA 6280003
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Göteborg University
Study Sponsor  ICMJE Göteborg University
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Berit Kriström, MDUmeå University Hospital
Principal Investigator:Nils-Östen Nilsson, MDHalmstad Department of Pediatrics
Principal Investigator:Maria Halldin, MDUppsala University Hospital
Principal Investigator:Sten Ivarsson, MD, ProfMalmö Academic Hospital
Principal Investigator:Kerstin Albertsson-Wikland, MD, profGothenburg University, Departments of pediatrics
PRS Account Göteborg University
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP